Author
Wei‐Wen Su
Also Known As
Chia-Jui Yen, Chih‐Lin Lin, Hsu-Heng Yen, Jia-Horng Kao, W Su, W. Su, W.-W. Su, W.W. Su, Wei-Wen Su, Wei‐Wen Su
143
Publications
4K
Citations
28
H-Index
47
Concepts
All Affiliations
| # | Concept | H-Index | Publications | Citations |
|---|---|---|---|---|
1 | Medicine | 13 | 17 | 1.4K |
2 | Epidemiology | 6 | 6 | 103 |
3 | Health Sciences | 3 | 3 | 535 |
4 | Cell Biology | 1 | 1 | 16 |
5 | Diabetes | 1 | 1 | 68 |
Wei‐Wen Su
×
56
Publications
3K
Citations
26
H-Index
| Year | Citations | |
|---|---|---|
2020 | 438 | |
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial Shukui Qin, Minshan Chen, Ann‐Lii Cheng, Surgical OncologyHepatologyMedicinePathologyHigh-risk Hepatocellular Carcinoma | 2023 | 415 |
2016 | 217 | |
2008 | 212 | |
2008 | 165 | |
2006 | 134 | |
2006 | 86 | |
2022 | 68 | |
2013 | 66 | |
2006 | 65 |
Page 1
Page 1